About Biolexis Therapeutics
Biolexis Therapeutics is a company based in Salt Lake City (United States) founded in 2021 by David J Bearss and Hariprasad Vankayalapati.. Biolexis Therapeutics has raised $12.5 million across 4 funding rounds from investors including Clarke Capital Partners. Biolexis Therapeutics offers products and services including Anti-obesity drugs, AMPK activators, mTORC inhibitors, and TNIK inhibitors. Biolexis Therapeutics operates in a competitive market with competitors including Medeloop, Pure Biologics, Hyku Biosciences, Sirion Biotech and Taizhou Baiying Biotechnology, among others.
- Headquarter Salt Lake City, United States
- Founders David J Bearss, Hariprasad Vankayalapati
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biolexis Therapeutics
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$12.5 M (USD)
in 4 rounds
-
Latest Funding Round
$10 M (USD), Series A
Nov 22, 2023
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biolexis Therapeutics
Biolexis Therapeutics offers a comprehensive portfolio of products and services, including Anti-obesity drugs, AMPK activators, mTORC inhibitors, and TNIK inhibitors. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets GLP-1 for obesity treatment and reduces side effects.
Activates protein kinase for obesity and overall health benefits.
Inhibits pathways to address longevity and chronic diseases.
Develops inhibitors for metabolic and related health issues.
Unlock access to complete
Unlock access to complete
Funding Insights of Biolexis Therapeutics
Biolexis Therapeutics has successfully raised a total of $12.5M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $10.0M
-
First Round
First Round
(14 Feb 2022)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2023 | Amount | Series A - Biolexis Therapeutics | Valuation | Clarke Capital Partners |
|
| Oct, 2023 | Amount | Seed - Biolexis Therapeutics | Valuation |
investors |
|
| Sep, 2022 | Amount | Seed - Biolexis Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Biolexis Therapeutics
Biolexis Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Clarke Capital Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment expertise is utilized by Clarke Capital Partners to grow businesses.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Biolexis Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Biolexis Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biolexis Therapeutics Comparisons
Competitors of Biolexis Therapeutics
Biolexis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Medeloop, Pure Biologics, Hyku Biosciences, Sirion Biotech and Taizhou Baiying Biotechnology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drug discovery services are offered by Medeloop as a CRO.
|
|
| domain | founded_year | HQ Location |
Specialized CRO with expertise in recombinant protein production and purification
|
|
| domain | founded_year | HQ Location |
Covalent medicines platform is advanced for drug discovery targeting proteins.
|
|
| domain | founded_year | HQ Location |
Customized AAV-based viral vectors for gene therapy are supplied.
|
|
| domain | founded_year | HQ Location |
Antibody-drug research and development services are provided.
|
|
| domain | founded_year | HQ Location |
Drug discovery services are provided to pharmaceutical and biotech clients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Biolexis Therapeutics
Frequently Asked Questions about Biolexis Therapeutics
When was Biolexis Therapeutics founded?
Biolexis Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is Biolexis Therapeutics located?
Biolexis Therapeutics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Is Biolexis Therapeutics a funded company?
Biolexis Therapeutics is a funded company, having raised a total of $12.5M across 4 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on Feb 14, 2022.
What does Biolexis Therapeutics do?
Biolexis Therapeutics was founded in 2021 and is based in Salt Lake City, United States. Operations are centered on contract research organization services within the biotechnology sector. Drug discovery efforts for small molecule therapeutics are emphasized, with support provided for early-stage development processes. Co-founders David J. Bearss and Hariprasad Vankayalapati lead the initiative focused on advancing therapeutic innovations.
Who are the top competitors of Biolexis Therapeutics?
Biolexis Therapeutics's top competitors include Medeloop, Pure Biologics and Centivax.
What products or services does Biolexis Therapeutics offer?
Biolexis Therapeutics offers Anti-obesity drugs, AMPK activators, mTORC inhibitors, and TNIK inhibitors.
Who are Biolexis Therapeutics's investors?
Biolexis Therapeutics has 1 investor. Key investors include Clarke Capital Partners.